A range of information needs should be met in order to better understand and predict the longevity/existence of novel psychoactive substances (NPS). This conceptual paper argues that one way of assessing how long a molecule may be around is to document how the life cycles or natural histories of 'traditional' drugs and NPS evolve. The earliest indication of the possible appearance of a new substance might be evidenced on the DeepWeb. However, this means they are less visible, in line with the clandestine nature of drug use and supply. Therefore, monitoring discussion groups/fora needs the development of new methods compared to those used in the Surface Net.
| WHY DO WE NEED TO KNOW NOW ABOUT THE LONGEVITY/EXISTENCE OF NOVEL PSYCHOACTIVE SUBSTANCES (NPS)?
New or novel psychoactive substances (NPS) are not a recent phenomenon. In the latter decades of the 20th century, new psychoactive substances such as ecstasy (MDMA), 'crack' cocaine, and methylamphetamine emerged onto the international recreational drug scene. The phenethylamine 2C-T-7, first synthesized in 1986, was described in detail in the Shulgins' PIKHAL book (Shulgin & Shulgin, 1991) leading to dissemination of data relating to it. By 1997, it was possible to purchase this compound from Dutch and German 'smart'
shops. Street-level availability was very low by the early 2000s, but a survey of Internet websites indicated a somewhat different scenario both in terms of information about it and opportunities for purchase (Schifano et al., 2002) . Since 2005, there have been only occasional confiscations and case reports or academic papers concerning 2C-T-7.
However, during the first decade of the present century, the 'noughties', there was a marked step change in this phenomenonan increasingly accelerated rate of appearance of new or novel substances contrasted with the substances above which are now part of the 'traditional' or established drug scene. Since 2005, this development has been accompanied by increases in the number and variety of molecules and products offered to (potential) consumers (EMCDDA-EUROPOL, 2016; UNODC, 2016) . At present, there appears to be little prospect of the situation changing in the short term.
The accelerating speed and extent of these changes is causing a number of important challenges to various constituencies or stakeholders including: policy-makers, law enforcement agencies, treatment services, epidemiologists, communities and, not least of all, consumers.
The key challenges are: how are NPS being created or 'discovered'; what is appearing and when; are they related to existing known molecules; who is producing them and where; how are NPS being adver- Briefly, these challenges arise from the fact that most NPS are unknown quantities in that they have not been subject to any type(s) of prior testing; therefore, their psychoactive properties (if any), pharmacological, neurophysiological, neuropsychological, psychopharmacological, toxicological, and addiction potential attributes remain unclear. Furthermore, the contents of NPS/'legal high' products offered for sale are unknown to law enforcement agencies, retailers,
| CONCEPTUAL APPROACH
A common approach in describing the stages in the production and consumption of goods is to look at their journey using such metaphors as "from field to fork" or "life is a journey" from "birth to death" or "cradle to grave." In the psychoactive substances field, we developed a conceptual framework for classifying mortality associated with each stage of the khat plant's journey from its cultivation, transportation, and consumption to its effects on the human body. Specifically, we utilized evidence abstracted from observed phenomena derived from a range of sources along that journey to provide a vehicle to identify factors that may impact on the phenomenon of khat-related mortality (Corkery et al., 2011) .
It is now proposed that a similar approach could be applied to the phenomenon of psychoactive substances, both 'traditional' and 'novel'/'new' . The aim would be to identify initially what the overall timeline and scale is for psychoactive substances, especially 'legal highs'/NPS, from original concept or creation through to death (of human individuals), or even beyond, that is, their survival, demise, or change following regulation/control. So far as can be ascertained from Internet searches using Google and Google Scholar, this is the first time this approach has been mooted in the published literature in the field of substance (ab)use.
However, the notion of "cradle to grave" tracking or monitoring over the life cycle of investigational/experimental products is used in the field of pharmaceutics for accountability, reconciliation, destruction, etc. throughout a product's life cycle (Edwards, 2008; Ma & English, 2007) . The word 'generation' has been used in recent years to describe new psychoactive products and molecules created and released to replace those existing ones coming under control as a result of legislative actions.
The term 'drug epidemic cycle' (Rose, Leonard, Norman, & Flanagan, 2015) has been used to describe the process by which a 'recreational' drug is first used within a narrowly defined population or community before becoming mainstream (e.g., the use of methamphetamine in the 'gay' community before moving into the 'club scene') possibly because of its perceived safety, desired effects, and legality before leading to adverse health consequences, then controls, and perhaps leading to reduced consumption. However, this notion does not capture the possibility of re-emergence. Furthermore, 'epidemic' is an inaccurate term in this context. 
| HOW COULD THIS RESEARCH BE DONE?
Both retrospective and prospective collection of data on NPS and other substances, including those already regulated or controlled would be required in order to get a complete profile of 'traditional' and newly emerging/re-emerging psychoactive substances. Prospective data collection would have to be undertaken on a regular and systematic basis, perhaps with a periodicity as short as a week.
We conjecture that data pointing to the existence of new NPS would first emerge on the DeepWeb-especially DeepNets-before appearing on the Surface Net (Internet) and will be less visible, in line with the clandestine nature of drug use and supply. Therefore, it might be sensible to monitor discussion groups/fora (across several domains/ areas of interest-not just users) at specified intervals, say every 2 or 3 weeks, and to take copies/snapshots of the sites/web pages to see how things develop over time and also to see how long it takes before substances are found on the Surface Net.
Methods for online monitoring of the Internet developed by previous projects such as Psychonaut (Deluca et al., 2012) , ReDNet (Corazza et al. 2013) , and EU-MADNESS (http://www.eumadness. Table 1. Access to other data, including databases, professional networks, and access to informed stakeholders such as members of early warning systems would need to be developed and maintained so that detailed information relating to the data given in Table 1 can be collected on a systematic and routine basis. The types of data to be collected would need to be agreed by participating researchers and data providers, along with data sharing and confidentiality protocols, etc.
Compilation of data from this multidisciplinary approach should be centrally coordinated and held in secure conditions with appropriate levels of access.
The aim of the data collection would be to collect data that will lend themselves to the development of mathematical models that will validate existing and new knowledge of 'traditional' recreational substances and facilitate predictions regarding the likely stages and timescales in the life cycles of NPS.
| LIKELY OUTCOMES OF SUCH RESEARCH
There may be different timescales for different types of 'traditional'
and legal drugs as well as NPS. Old medicines discontinued because 
